Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance

M Kohli, I Schiller, N Dendukuri… - Cochrane Database …, 2018 - cochranelibrary.com
Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

M Kohli, I Schiller, N Dendukuri, K Dheda… - 2018 - cabidigitallibrary.org
Background: Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

M Kohli, I Schiller, N Dendukuri… - COCHRANE …, 2018 - researchonline.lshtm.ac.uk
BACKGROUND: Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

[PDF][PDF] Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance

M Kohli, I Schiller, N Dendukuri, K Dheda… - status and date: New …, 2018 - researchgate.net
Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

[PDF][PDF] Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance

M Kohli, I Schiller, N Dendukuri, K Dheda… - status and date …, 2018 - core.ac.uk
Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

[HTML][HTML] Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance

M Kohli, I Schiller, N Dendukuri, K Dheda… - The Cochrane …, 2018 - ncbi.nlm.nih.gov
Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance

M Kohli, I Schiller, N Dendukuri… - The Cochrane …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance

M Kohli, I Schiller, N Dendukuri, H Ryan… - Cochrane Database …, 2017 - archive.lstmed.ac.uk
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as
follows: To determine the diagnostic accuracy of Xpert® MTB/RIF for the detection of …

Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

M Kohli, I Schiller, N Dendukuri, K Dheda… - The Cochrane …, 2018 - europepmc.org
Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

[PDF][PDF] Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance

M Kohli, I Schiller, N Dendukuri, H Ryan… - status and date: New …, 2017 - core.ac.uk
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Protocol) Page
1 Cochrane Database of Systematic Reviews Xpert® MTB/RIF assay for extrapulmonary …